In 2022 and 2023, the European Commission introduced new restrictions on retinol and retinyl esters in cosmetic products, following a safety assessment by the Scientific Committee on Consumer Safety (SCCS). The changes have caused genuine confusion in the skincare community, partly because the science behind them is debated and partly because they affect products people have been using without incident. Understanding what changed, why, and what it means practically for your routine is worth clarifying properly.
What changed and when
The EU’s changes to retinol concentration limits came in two phases, following SCCS opinion documents from 2016 and 2022. The final restrictions, which took effect in stages through 2023 and 2025, limit retinol (vitamin A alcohol) in cosmetics to:
- 0.3% in face care products
- 0.05% in body lotions and other body care products
- Retinol is prohibited in products intended for use on children under 3 years and in sunscreens
- Vitamin A (as retinyl esters) was limited, with retinyl acetate and retinyl palmitate set at specific limits based on estimated daily exposure
Additionally, any product containing retinol above certain concentrations must display a warning that the product should not be used by pregnant women and should not be applied near the eyes. The EU also requires SPF usage advice on high-retinol products.
The science behind the decision
The SCCS opinion focused on two primary concerns: systemic vitamin A accumulation and photogenotoxicity.
Vitamin A is a fat-soluble vitamin that accumulates in the liver. Excessive systemic vitamin A from all sources (diet, supplements, and topical products combined) can cause hypervitaminosis A, a condition involving liver toxicity, bone changes, and in pregnant women, fetal harm. The SCCS assessed the potential for topical retinol to contribute meaningfully to total vitamin A exposure and concluded that at higher concentrations, particularly in body products applied over large areas, this contribution could be significant for some population groups.
Photogenotoxicity, the potential for a substance to damage DNA when combined with UV exposure, was also assessed. The SCCS concluded that retinol has photogenotoxic potential under certain experimental conditions. This finding is disputed by some dermatologists and cosmetic scientists, who argue the experimental conditions used do not reflect real-world topical application.
The pregnancy caution reflects existing dermatological guidance: retinoids are contraindicated in pregnancy due to teratogenicity, primarily established for oral retinoids (isotretinoin) but extended cautiously to topical application.
The debate around the restrictions
Many dermatologists and cosmetic scientists have publicly disagreed with the SCCS conclusions, particularly the photogenotoxicity finding. The concern is that the restrictions are not proportionate to the demonstrated real-world risk from cosmetic retinol use at concentrations that have been used safely in clinical practice for decades.
Tretinoin (retinoic acid) at 0.025-0.1%, which is considerably more potent and biologically active than retinol, has a long safety record in clinical use. The argument made by critics of the new limits is that retinol at 0.3% is substantially less biologically active than tretinoin at even 0.025%, meaning the risk profile assumed by the SCCS may be significantly overstated.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) and some other regulatory bodies have not implemented equivalent restrictions, creating a divergence between EU and non-EU markets that affects product availability and formulation decisions for brands selling across multiple markets.
What this means for products you already use
Products that were formulated at higher retinol concentrations (some brands sold 0.5% or 1% retinol in face serums in EU markets) needed reformulation or withdrawal from EU markets. If you were using a product at concentrations above 0.3% for face or 0.05% for body and you live in the EU, the product may have been reformulated or may no longer be available in its original form.
At 0.3% retinol, the new EU limit is still a concentration that can produce meaningful skincare results with consistent use. It is lower than what clinical research has often used (typically 0.3-1% in published studies), but the dose-response relationship for retinol is not linear; there is significant benefit at lower concentrations, and skin adapts to and tolerates lower concentrations better than higher ones.
Products containing retinyl palmitate or retinyl acetate (the ester forms of vitamin A, which are weaker than retinol and converted through multiple steps) now have their own concentration limits. Many products previously used these esters at low concentrations as gentle retinoid sources; these can still be used within the new limits.
Practical navigation for your routine
If you are in the EU and have been using retinol at concentrations above the new limits, transitioning to products formulated within the new rules is the straightforward response. The 0.3% limit for facial use is workable for a meaningful skincare effect, particularly for people who have been using retinol for some time and whose skin has adapted.
For those seeking the results that higher retinol concentrations were producing, alternatives within the retinoid family that are not currently restricted in the same way include:
- Retinaldehyde (retinal): not currently under the same restrictions as retinol, and one conversion step closer to retinoic acid, meaning it is more potent per concentration unit
- Bakuchiol: a plant-derived retinoid alternative with growing evidence, no EU restrictions, and good tolerability for sensitive skin
- Prescription tretinoin: available through dermatologist prescription and not restricted under cosmetic regulations
The EU restrictions apply to cosmetic products, not pharmaceutical products. Tretinoin prescribed by a dermatologist remains available and is not affected by these cosmetics regulations.
The transparent view
The EU retinol restrictions reflect a cautious regulatory approach in the face of specific safety concerns, some of which are disputed by practitioners who have observed long clinical use without the risks the restrictions imply. For most consumers using retinol within the new limits, the practical impact is on product formulation rather than safety outcomes. The skin benefit of retinol at 0.3% in a well-formulated product is real; the restrictions do not make retinol ineffective, they limit the ceiling of what over-the-counter products can contain.